SG11202000484TA - Cd38 antibody - Google Patents
Cd38 antibodyInfo
- Publication number
- SG11202000484TA SG11202000484TA SG11202000484TA SG11202000484TA SG11202000484TA SG 11202000484T A SG11202000484T A SG 11202000484TA SG 11202000484T A SG11202000484T A SG 11202000484TA SG 11202000484T A SG11202000484T A SG 11202000484TA SG 11202000484T A SG11202000484T A SG 11202000484TA
- Authority
- SG
- Singapore
- Prior art keywords
- stevenage
- tusk
- catalyst
- international
- therapeutics
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762546336P | 2017-08-16 | 2017-08-16 | |
| US201762582609P | 2017-11-07 | 2017-11-07 | |
| PCT/EP2018/072272 WO2019034753A1 (en) | 2017-08-16 | 2018-08-16 | ANTIBODY CD38 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202000484TA true SG11202000484TA (en) | 2020-02-27 |
Family
ID=63259520
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202000484TA SG11202000484TA (en) | 2017-08-16 | 2018-08-16 | Cd38 antibody |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11236173B2 (https=) |
| EP (1) | EP3668543A1 (https=) |
| JP (1) | JP7299873B2 (https=) |
| KR (1) | KR102770110B1 (https=) |
| CN (1) | CN111032086B (https=) |
| AU (1) | AU2018316522B2 (https=) |
| CA (1) | CA3072296A1 (https=) |
| SG (1) | SG11202000484TA (https=) |
| WO (1) | WO2019034753A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200345725A1 (en) | 2019-01-11 | 2020-11-05 | Omeros Corporation | Methods and Compositions for Treating Cancer |
| WO2020185859A1 (en) | 2019-03-12 | 2020-09-17 | Arcus Biosciences, Inc. | Treatment of oncogene-driven cancers |
| US12310965B2 (en) | 2019-03-29 | 2025-05-27 | Arcus Biosciences, Inc. | Treatment of cancer utilizing an identified adenosine fingerprint |
| WO2021003074A1 (en) | 2019-07-03 | 2021-01-07 | Crystal Bioscience Inc. | Anti-cd38 antibody and methods of use thereof |
| US12181485B2 (en) | 2020-09-10 | 2024-12-31 | CASI Pharmaceuticals, Inc | Methods of blood screening |
| CN112300281B (zh) * | 2020-10-29 | 2021-06-11 | 杭州爱唯生命科技有限公司 | 含有nk细胞的药物组合物及其治疗癌症的用途 |
| CN114437215B (zh) * | 2020-11-05 | 2023-02-07 | 上海麦济生物技术有限公司 | 抗人cd38抗体及其制备方法和用途 |
| WO2025213286A1 (zh) * | 2024-04-07 | 2025-10-16 | 中国医学科学院血液病医院(中国医学科学院血液学研究所) | 一种阻断单核巨噬细胞功能的cd38抑制剂在治疗itp中的应用 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020164788A1 (en) | 1994-12-02 | 2002-11-07 | The Wellcome Foundation Limited | Humanized antibodies to CD38 |
| AU2011202520C1 (en) | 2002-10-17 | 2016-02-18 | Genmab A/S | Human monoclonal antibodies against CD20 |
| US9200061B2 (en) | 2004-02-06 | 2015-12-01 | Morpho Sys AG | Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i |
| DK2511297T3 (en) | 2004-02-06 | 2015-06-15 | Morphosys Ag | Human anti-CD38 antibodies and their applications |
| US8263746B2 (en) | 2004-02-06 | 2012-09-11 | Morphosys Ag | Anti-CD38 human antibodies and uses thereof |
| EP2567976B1 (en) | 2005-03-23 | 2017-07-19 | Genmab A/S | Antibodies against CD38 for treatment of multiple myeloma |
| TW200745162A (en) | 2005-05-24 | 2007-12-16 | Morphosys Ag | Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38 |
| EP2860192B1 (en) | 2005-10-12 | 2017-09-27 | MorphoSys AG | Generation and profiling of fully human HuCAL GOLD-derived therapeutic antibodies specific for human CD38 |
| AU2016228249A1 (en) | 2006-09-26 | 2016-10-06 | Genmab A/S | Combination treatment of CD38-expressing tumors |
| AU2013209322A1 (en) | 2006-10-19 | 2013-08-15 | Sanofi-Aventis | Novel anti-cd38 antibodies for the treatment of cancer |
| EP1914242A1 (en) * | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| KR101552735B1 (ko) | 2006-12-01 | 2015-09-14 | 메다렉스, 엘.엘.시. | 씨디22에 결합하는 인간 항체 및 이의 용도 |
| CN101605906A (zh) | 2006-12-14 | 2009-12-16 | 梅达雷克斯公司 | 结合cd70的人类抗体及其用途 |
| KR20090088946A (ko) | 2006-12-14 | 2009-08-20 | 메다렉스, 인코포레이티드 | 씨디70에 결합하는 인간 항체 및 이의 용도 |
| CN103536915A (zh) | 2006-12-27 | 2014-01-29 | 埃默里大学 | 用于治疗传染病和肿瘤的组合物和方法 |
| US8877688B2 (en) | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
| US8691730B2 (en) | 2007-09-14 | 2014-04-08 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
| AU2009301580B2 (en) | 2008-10-06 | 2015-11-26 | The University Of British Columbia | Methods and systems for predicting misfolded protein epitopes |
| SG178925A1 (en) | 2009-09-22 | 2012-04-27 | Volker Sandig | Process for producing molecules containing specialized glycan structures |
| DK2593594T3 (en) | 2010-07-16 | 2017-12-11 | Adimab Llc | ANTIBODY LIBRARIES |
| UA112170C2 (uk) * | 2010-12-10 | 2016-08-10 | Санофі | Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб |
| JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| GB201302447D0 (en) | 2013-02-12 | 2013-03-27 | Oxford Biotherapeutics Ltd | Therapeutic and diagnostic target |
| EP2970471A2 (en) | 2013-03-15 | 2016-01-20 | F. Hoffmann-La Roche AG | Anti-crth2 antibodies and their use |
| JP6775422B2 (ja) * | 2014-03-28 | 2020-10-28 | ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． | Ｃｄ３８及びｃｄ３に結合する二重特異性抗体 |
| MA40894A (fr) | 2014-11-04 | 2017-09-12 | Glenmark Pharmaceuticals Sa | Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production |
| WO2016089862A1 (en) | 2014-12-01 | 2016-06-09 | The Trustees Of The University Of Pennsylvania | Dna antibody constructs and method of using same |
| ES2927119T3 (es) * | 2015-04-08 | 2022-11-02 | Sorrento Therapeutics Inc | Productos terapéuticos de anticuerpos que se unen a CD38 |
| GB201506389D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
| HRP20240338T1 (hr) | 2015-06-24 | 2024-05-24 | Janssen Biotech, Inc. | Imunomodulacija i liječenje solidnih tumora s protutijelima koja se specifično vežu na cd38 |
| CA2997444A1 (en) | 2015-09-29 | 2017-04-06 | Amgen Inc. | Asgr inhibitors for reducing cholesterol levels |
| PE20240096A1 (es) | 2015-10-02 | 2024-01-18 | Hoffmann La Roche | Anticuerpos biespecificos especificos para un receptor de tnf coestimulador |
| US12590171B2 (en) | 2019-09-27 | 2026-03-31 | Nanjing GenScript Biotech Co., Ltd. | Anti-VHH domain antibodies and use thereof |
-
2018
- 2018-08-16 AU AU2018316522A patent/AU2018316522B2/en active Active
- 2018-08-16 KR KR1020207003078A patent/KR102770110B1/ko active Active
- 2018-08-16 SG SG11202000484TA patent/SG11202000484TA/en unknown
- 2018-08-16 JP JP2020508320A patent/JP7299873B2/ja active Active
- 2018-08-16 WO PCT/EP2018/072272 patent/WO2019034753A1/en not_active Ceased
- 2018-08-16 CA CA3072296A patent/CA3072296A1/en active Pending
- 2018-08-16 CN CN201880051751.2A patent/CN111032086B/zh active Active
- 2018-08-16 US US16/638,205 patent/US11236173B2/en active Active
- 2018-08-16 EP EP18756417.4A patent/EP3668543A1/en active Pending
-
2022
- 2022-01-18 US US17/578,014 patent/US12162949B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR20200036861A (ko) | 2020-04-07 |
| US20220135697A1 (en) | 2022-05-05 |
| AU2018316522A1 (en) | 2020-03-05 |
| US20200362050A1 (en) | 2020-11-19 |
| NZ761838A (en) | 2025-03-28 |
| US12162949B2 (en) | 2024-12-10 |
| CA3072296A1 (en) | 2019-02-21 |
| CN111032086B (zh) | 2023-09-26 |
| AU2018316522B2 (en) | 2025-02-20 |
| WO2019034753A1 (en) | 2019-02-21 |
| EP3668543A1 (en) | 2020-06-24 |
| CN111032086A (zh) | 2020-04-17 |
| KR102770110B1 (ko) | 2025-02-20 |
| JP2020533965A (ja) | 2020-11-26 |
| US11236173B2 (en) | 2022-02-01 |
| JP7299873B2 (ja) | 2023-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11202000484TA (en) | Cd38 antibody | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11202000321PA (en) | Cd38 modulating antibody | |
| SG11201803956UA (en) | Anti-dr5 antibodies and methods of use thereof | |
| SG11201903857UA (en) | Antibodies to pd-1 and uses thereof | |
| SG11201806992VA (en) | Antibodies to tigit | |
| SG11201908056QA (en) | Anti-par2 antibodies and uses thereof | |
| SG11201810927QA (en) | Pd-l1-specific antibodies and methods of using the same | |
| SG11201810933QA (en) | Anti-c5 antibodies and uses thereof | |
| SG11201906853QA (en) | Anti-rsv monoclonal antibody formulation | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201907848YA (en) | Antibodies binding to vista at acidic ph | |
| SG11201900885VA (en) | Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule | |
| SG11201908578YA (en) | Fc-optimized anti-cd25 for tumour specific cell depletion | |
| SG11201906961UA (en) | Polypeptide variants and uses thereof | |
| SG11201809064QA (en) | Chimeric neurotoxins | |
| SG11201901899PA (en) | Bispecific trivalent antibodies binding to claudin6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases | |
| SG11201903454VA (en) | Immunologically discernible cell surface variants for use in cell therapy | |
| SG11201907889YA (en) | Glycan-interacting compounds and methods of use | |
| SG11201806496SA (en) | Antigen binding proteins that bind pd-l1 | |
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11201808724SA (en) | Anti-tim-3 antibodies and compositions | |
| SG11201906386XA (en) | Combination therapy involving diaryl macrocyclic compounds | |
| SG11201810420YA (en) | Antibodies to alpha-synuclein and uses thereof | |
| SG11201908326YA (en) | Methods of treating neurodegenerative diseases |